4.5 Review

The Use of Physiologically Based Pharmacokinetic Analyses-in Biopharmaceutics Applications -Regulatory and Industry Perspectives

期刊

PHARMACEUTICAL RESEARCH
卷 39, 期 8, 页码 1681-1700

出版社

SPRINGER/PLENUM PUBLISHERS
DOI: 10.1007/s11095-022-03280-4

关键词

biopharmaceutics; clinically relevant dissolution; critical bioavailability attributes; critical quality attributes; PBBM; PBPK

向作者/读者索取更多资源

The use of physiologically based biopharmaceutics modeling (PBBM) to support drug product quality attributes is an evolving field with growing interest. Establishing an in vitro-in vivo link is crucial for achieving patient centric quality standards. While PBBM offers advantages, there are challenges that require further improvements. Collaboration between regulatory, industry, and academic fields can advance the field and deliver on the promises of PBBM in establishing patient centric quality standards.
The use of physiologically based pharmacokinetic (PBPK) modeling to support the drug product quality attributes, also known as physiologically based biopharmaceutics modeling (PBBM) is an evolving field and the interest in using PBBM is increasing. The US-FDA has emphasized on the use of patient centric quality standards and clinically relevant drug product specifications over the years. Establishing an in vitroin vivo link is an important step towards achieving the goal of patient centric quality standard. Such a link can aid in constructing a bioequivalence safe space and establishing clinically relevant drug product specifications. PBBM is an important tool to construct a safe space which can be used during the drug product development and lifecycle management. There are several advantages of using the PBBM approach, though there are also a few challenges, both with in vitro methods and in vivo understanding of drug absorption and disposition, that preclude using this approach and therefore further improvements are needed. In this review we have provided an overview of experience gained so far and the current perspective from regulatory and industry point of view. Collaboration between scientists from regulatory, industry and academic fields can further help to advance this field and deliver on promises that PBBM can offer towards establishing patient centric quality standards.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据